Clinical Consequences of an Individualized Dialysate Sodium Prescription in Hemodialysis Patients
Overview
Authors
Affiliations
Background: Predialysis plasma sodium (Na(+)) concentration is relatively constant in hemodialysis (HD) patients, and a higher dialysate Na(+) concentration can promote an increase in the interdialytic fluid ingestion to achieve an individual's osmolar set point, and individualization of dialysate Na(+) concentration may improve interdialytic weight gain (IDWG), blood pressure (BP), and HD-related symptoms.
Methods: Twenty-seven nondiabetic, non-hypotension prone HD patients were enrolled in a single-blind crossover study. Subjects underwent nine consecutive HD sessions with the dialysate Na(+) concentration set to 138 mEq/L (standard Na(+) HD), followed by nine sessions wherein the dialysate Na(+) was set to match the patients average pre-HD plasma Na(+) measured three times during the standard Na(+) phase multiplied by 0.95 (individualized dialysate Na(+) HD). Dry weight, dialysis prescription, and medications were not modified during the six weeks of the study.
Results: Pre-HD Na(+) was similar in both periods of the study (standard Na(+) HD, 134.0 +/- 1.4 mEq/L; individualized Na(+) HD, 134.0 +/- 1.5 mEq/L; P= 0.735). There was a significant decrease in interdialytic weight gain (2.91 +/- 0.87 kg vs. 2.29 +/- 0.65 kg; P< 0.001), interdialytic thirst scores, and episodes of intradialytic hypotension in the individualized Na(+) period compared with the standard phase. Pre-HD BP was lower in individualized Na(+) HD in patients with uncontrolled BP at baseline (N= 15), but not in those with controlled BP at baseline (N= 12) (DeltaBP -15.6/-6.5 mm Hg in uncontrolled vs. DeltaBP +6.4/+4.5 mm Hg in controlled, P= <0.001 for systolic BP and P= <0.001 for diastolic BP).
Conclusion: An individualized Na(+) dialysate based on predialysis plasma Na(+) levels decreases thirst, IDWG, HD-related symptoms, and pre-HD BP (in patients with uncontrolled BP at baseline).
Bratsiakou A, Iatridi F, Theodorakopoulou M, Sarafidis P, Goumenos D, Papachristou E Clin Kidney J. 2024; 17(8):sfae041.
PMID: 39135940 PMC: 11317838. DOI: 10.1093/ckj/sfae041.
Iatridi F, Malandris K, Ekart R, Xagas E, Karpetas A, Theodorakopoulou M Nephrol Dial Transplant. 2024; 39(11):1900-1910.
PMID: 38710537 PMC: 11522792. DOI: 10.1093/ndt/gfae104.
Bossola M, Mariani I, Sacco M, Antocicco M, Pepe G, Di Stasio E Int Urol Nephrol. 2024; 56(7):2313-2323.
PMID: 38446246 PMC: 11189964. DOI: 10.1007/s11255-024-03972-3.
Resistant Hypertension in Dialysis: Epidemiology, Diagnosis, and Management.
Georgianos P, Agarwal R J Am Soc Nephrol. 2024; 35(4):505-514.
PMID: 38227447 PMC: 11000742. DOI: 10.1681/ASN.0000000000000315.
Feedback control in hemodialysis.
Randhay A, Eldehni M, Selby N Semin Dial. 2023; 38(1):62-70.
PMID: 37994191 PMC: 11867153. DOI: 10.1111/sdi.13185.